Gan & Lee Pharmaceuticals Co., Ltd. (hereinafter referred to as Gan & Lee, stock code: 603087.SH) participated in the 58th Annual Meeting of the European Association for the Study of Diabetes(EASD) at Stockholmsmässan in Stockholm, Sweden on September 19-23, 2022. The hybrid congress attracted top-class doctors, scientists and healthcare professionals from all over the world to join the event in person or virtually. Focused on diabetes, it provides an opportunity for the medical community to learn about cutting-edge technologies, ground-breaking study results and significant advances in treatment and care.

The European Association for the Study of Diabetes is a non-profit, medical scientific association. It was founded in 1965 and its headquarters is based in Duesseldorf, Germany. The aims of the Association are to encourage and support research in the field of diabetes, the rapid diffusion of acquired knowledge and to facilitate its application. The EASD Annual Meeting is the largest and most prestigious diabetes conference in Europe, held in different European cities annually.

The meeting features symposia, e-learning, oral presentations, short oral discussions, industry exhibitions, etc. Among them, the three-day exhibition provides a good platform of exchange and interaction for exhibitors and professionals in diabetes. During the exhibition, Gan & Lee received a large number of industry experts at its booth. We had a discussion with Delphine Sartiaux and Dominique Robert from IDF on how to further deepen the partnership between the two sides. In addition, Simon Michel, CEO of Ypsomed said he hopes to strengthen partnership and looks forward to seeing our insulin products land in the U.S. and EU as soon as possible.The vice president and COO of Gan & Lee USA, Gary J. Furda said: "We have drawn widespread attention from the community and the Gan & Lee brand awareness has been raised at EASD. Our insights into unmet clinical needs will carry us forward. Hope to see you next year in Hamburg.”

Currently Gan & Lee's three biosimilar insulins, glargine, lispro and aspart have completed a number of clinical trials in a few clinical centers in Europe and the US.We are now preparing Biologic License Application(BLA) in the US and clinical trial applications in Europe. We hope that the three compounds can be approved in the future to benefit more diabetic patients. At the same time, Gan & Lee is also actively expanding its product pipeline and is committed to drug development in the fields of cardiovascular disease and oncology. In the future, we will continue to provide more diversified high-quality products for the patients around the world.

Reference: 

Scientific Programme Information from:https://www.easd.org/annual-meeting/easd-2022.html 

About Gan & Lee

Gan & Lee Pharmaceuticals has developed the first Chinese domestic biosynthetic human insulin. Currently, we have five recombinant insulin analogs commercialized in China including long-acting glargine injection (Basalin^®), fast-acting lispro injection (Prandilin^™), fast-acting aspart injection (Rapilin^®), mixed protamine zinc lispro injection (25R) (Prandilin^™25), aspart 30 injection (Rapilin^®30), and one human insulin injection - mixed protamine human insulin injection (30R) (Similin^®30). We have two approved medical devices in China, namely reusable insulin injection pen (GanleePen), and disposable pen needle (GanleeFine^®).

In the future, Gan & Lee strives to achieve a comprehensive coverage in the field of diabetes diagnosis and treatment. Moving forward to advance our goal of becoming a world-class pharmaceutical company, we will also take an active part in developing new chemical entities, and work on the treatment of cardiovascular diseases, metabolic diseases, cancer, and other therapeutics.